Switch from EFV + ZDV-3TC versus EFV + TDF-FTC

COMET Trial
Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC
COMET: Study Design

Study Design: COMET Study

- **Background**: Prospective, single-arm 24-week phase 4 switch study evaluating of switching from twice daily zidovudine-lamivudine to once daily tenofovir DF-emtricitabine in virologically suppressed patients on efavirenz

- **Inclusion Criteria (n = 402)**
  - Age ≥ 18 years
  - On EFV + ZDV-3TC for ≥ 8 weeks
  - HIV RNA < 400 copies/mL
  - CrCl ≥ 50 mL/min

- **Treatment (Switch) Arm**
  - Efavirenz-tenofovir DF-emtricitabine

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Result

Week 24: Virologic Response

Virologic Suppression (%)

Virologic Suppression Threshold

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Result

Week 24: Immunologic Response

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Result

Week 24: Patient-Reported Outcomes

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Conclusions

**Interpretation**: “Patients switched to EFV + TDF/FTC maintained virologic suppression and the regimen was well tolerated. Patients reported increased satisfaction with treatment and fewer were bothered by side effects.”

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.